Glen Hazlewood

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1297310/glen-hazlewood-publications-by-year.pdf
Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

112 papers	2,389 citations	24 h-index	47 g-index
137 ext. papers	3,201 ext. citations	4 avg, IF	5.08 L-index

#	Paper	IF	Citations
112	Perspectives of Pediatric Rheumatologists on Initiating and Tapering Biologics in Patients with Juvenile Idiopathic Arthritis: A Formative Qualitative Study.. *Patient*, **2022**, 1	3.7	
111	Development and testing of the rheumatoid arthritis quality of care survey.. *Seminars in Arthritis and Rheumatism*, **2022**, 54, 152002	5.3	
110	Evaluating Quality of Care for Rheumatoid Arthritis for the Population of Alberta Using System-level Performance Measures. *Journal of Rheumatology*, **2021**, 48, 482-485	4.1	3
109	National Priorities for High-quality Rheumatology Transition Care for Youth in Canada. *Journal of Rheumatology*, **2021**, 48, 426-433	4.1	3
108	Development of a Patient-centered Quality Measurement Framework for Measuring, Monitoring, and Optimizing Rheumatoid Arthritis Care in Canada. *Journal of Rheumatology*, **2021**, 48, 326-334	4.1	3
107	Priorities for High-quality Care in Rheumatoid Arthritis: Results of Patient, Health Professional, and Policy Maker Perspectives. *Journal of Rheumatology*, **2021**, 48, 486-494	4.1	5
106	Effectiveness of initial methotrexate-based treatment approaches in early rheumatoid arthritis: an elicitation of rheumatologistsQbeliefs. *Rheumatology*, **2021**, 60, 3570-3578	3.9	1
105	Systematic Review of Outcomes and Patient Experience with Virtual Care in Rheumatoid Arthritis. *Arthritis Care and Research*, **2021**,	4.7	2
104	Strategies for developing and implementing a rheumatoid arthritis healthcare quality framework: a thematic analysis of perspectives from arthritis stakeholders. *BMJ Open*, **2021**, 11, e043759	3	
103	Efficacy of Allogeneic Hematopoietic Cell Transplantation for Autoimmune Diseases. *Transplantation and Cellular Therapy*, **2021**, 27, 489.e1-489.e9		2
102	"Walking into the unknown key challenges of pregnancy and early parenting with inflammatory arthritis: a systematic review and thematic synthesis of qualitative studies. *Arthritis Research and Therapy*, **2021**, 23, 123	5.7	1
101	Development of an Implementation Strategy for Patient Decision Aids in Rheumatoid Arthritis Through Application of the Behavior Change Wheel. *ACR Open Rheumatology*, **2021**, 3, 312-323	3.5	2
100	Patient and Rheumatologist Perspectives on Tapering DMARDs in Rheumatoid Arthritis: A Qualitative Study. *Rheumatology*, **2021**,	3.9	1
99	Supporting Equity in Rheumatoid Arthritis Outcomes in Canada: Population-specific Factors in Patient-centered Care. *Journal of Rheumatology*, **2021**, 48, 1793-1802	4.1	1
98	POS0531 FACTORS ASSOCIATED WITH BASELINE HYPERTENSION IN EARLY RHEUMATOID ARTHRITIS: DATA FROM A REAL-WORLD LARGE INCIDENT COHORT. *Annals of the Rheumatic Diseases*, **2021**, 80, 499-500	2.4	
97	Canadian Rheumatology Association Recommendation for the Use of COVID-19 Vaccination for Patients With Autoimmune Rheumatic Diseases. *Journal of Rheumatology*, **2021**, 48, 1330-1339	4.1	13
96	OP0262-HPR THE NEURO-QOL UPPER EXTREMITY FUNCTION SCALE: NEW OPPORTUNITIES TO MORE RELIABLY AND PRECISELY MEASURE SELF-REPORTED HAND FUNCTION AND SELF-CARE ACTIVITIES IN PEOPLE WITH RA. *Annals of the Rheumatic Diseases*, **2021**, 80, 159.2-160	2.4	

95	POS1459-HPR IDENTIFYING MEANINGFUL CHANGE IN THE RA FLARE QUESTIONNAIRE SCORES IN RHEUMATOID ARTHRITIS. *Annals of the Rheumatic Diseases*, **2021**, 80, 1014-1015	2.4	0
94	Health Assessment Questionnaire at One Year Predicts All-Cause Mortality in Patients With Early Rheumatoid Arthritis. *Arthritis and Rheumatology*, **2021**, 73, 197-202	9.5	5
93	Improvements in Fatigue Lag Behind Disease Remission in Early Rheumatoid Arthritis: Results From the Canadian Early Arthritis Cohort. *Arthritis and Rheumatology*, **2021**, 73, 53-60	9.5	5
92	Model to Determine the Cost-Effectiveness of Screening Psoriasis Patients for Psoriatic Arthritis. *Arthritis Care and Research*, **2021**, 73, 266-274	4.7	3
91	Treatment Preferences for Cardiac Procedures of Patients With Chronic Kidney Disease in Acute Coronary Syndrome: Design and Pilot Testing of a Discrete Choice Experiment. *Canadian Journal of Kidney Health and Disease*, **2021**, 8, 2054358120985375	2.3	0
90	Patient preferences to value health outcomes in rheumatology clinical trials: Report from the OMERACT special interest group. *Seminars in Arthritis and Rheumatism*, **2021**, 51, 919-924	5.3	4
89	Adaptation of a Shared Decision-Making Tool for Early Rheumatoid Arthritis Treatment Decisions with Indigenous Patients. *Patient*, **2021**, 1	3.7	1
88	Informing the GRADE evidence to decision process with health equity considerations: demonstration from the Canadian rheumatoid arthritis care context. *Journal of Clinical Epidemiology*, **2021**, 138, 147-155	5.7	0
87	The Application of Preference Elicitation Methods in Clinical Trial Design to Quantify Trade-Offs: A Scoping Review.. *Patient*, **2021**, 1	3.7	0
86	Disease-modifying anti-rheumatic drugs for rheumatoid arthritis: a systematic review and network meta-analysis. *The Cochrane Library*, **2020**,	5.2	5
85	Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment. *PLoS ONE*, **2020**, 15, e0227635	3.7	11
84	Protocol for the development of guidance for stakeholder engagement in health and healthcare guideline development and implementation. *Systematic Reviews*, **2020**, 9, 21	3	30
83	FRI0024 HOW OFTEN DOES REACHING TARGET MISS THE MARK? LONGITUDINAL PATTERNS OF REMISSION IN REAL-WORLD EARLY RHEUMATOID ARTHRITIS PATIENTS. *Annals of the Rheumatic Diseases*, **2020**, 79, 584-585	2.4	
82	FRI0032 REGIONAL AND WIDESPREAD PATTERNS OF NON-ARTICULAR PAIN ARE COMMON AT RA DIAGNOSIS AND CONTRIBUTE TO POOR OUTCOMES AT 12 MONTHS: A PROSPECTIVE STUDY OF PAIN PATTERNS IN CANADIANS WITH RA. *Annals of the Rheumatic Diseases*, **2020**, 79, 589-590	2.4	
81	SAT0127 REAL-WORLD PREDICTORS OF STARTING DIFFERENT ADVANCED DMARD TREATMENTS IN RHEUMATOID ARTHRITIS: A PROSPECTIVE INVESTIGATION FROM THE CANADIAN EARLY ARTHRITIS COHORT (CATCH) GROUP. *Annals of the Rheumatic Diseases*, **2020**, 79, 999-1000	2.4	1
80	SAT0053 ESTIMATING REAL-WORLD UNMET NEEDS FOR REACHING REMISSION IN THE FIRST YEAR FOLLOWING EARLY RA DIAGNOSIS: RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT (CATCH). *Annals of the Rheumatic Diseases*, **2020**, 79, 958-959	2.4	
79	FRI0037 ALL-CAUSE MORTALITY IN EARLY RHEUMATOID ARTHRITIS PREDICTED BY HEALTH ASSESSMENT QUESTIONNAIRE AT ONE YEAR. *Annals of the Rheumatic Diseases*, **2020**, 79, 592.1-593	2.4	
78	FRI0030 MORE THAN HALF OF NEWLY DIAGNOSED RA PATIENTS ARE NOT CONVINCED OF THE NECESSITY OF RA MEDICINES: ASSOCIATIONS WITH RA CHARACTERISTICS, SYMPTOMS, AND FUNCTION IN THE CANADIAN EARLY ARTHRITIS COHORT (CATCH). *Annals of the Rheumatic Diseases*, **2020**, 79, 588.1-588	2.4	

77	OP0263-HPR MAJOR STRESSORS IN THE YEAR PRIOR TO RA DIAGNOSIS: IMPACT ON PATIENT-REPORTED OUTCOMES ONE YEAR LATER. *Annals of the Rheumatic Diseases*, **2020**, 79, 165.2-165	2.4	
76	Using a Discrete-Choice Experiment in a Decision Aid to Nudge Patients Towards Value-Concordant Treatment Choices in Rheumatoid Arthritis: A Proof-of-Concept Study. *Patient Preference and Adherence*, **2020**, 14, 829-838	2.4	9
75	GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. *BMJ, The*, **2020**, 371, m3900	5.9	27
74	Global Rural and Remote Patients with Rheumatoid Arthritis: A Systematic Review. *Arthritis Care and Research*, **2020**,	4.7	2
73	GRADE approach to drawing conclusions from a network meta-analysis using a partially contextualised framework. *BMJ, The*, **2020**, 371, m3907	5.9	17
72	Implementation and Evaluation of Audit and Feedback for Monitoring Treat-to-Target (T2T) Strategies in Rheumatoid Arthritis Using Performance Measures. *Rheumatology and Therapy*, **2020**, 7, 909-925	4.4	3
71	Multi-Modal Imaging to Assess the Interaction Between Inflammation and Bone Damage Progression in Inflammatory Arthritis. *Frontiers in Medicine*, **2020**, 7, 545097	4.9	2
70	Qualitative Study of Treatment Preferences for Rheumatoid Arthritis and Pharmacotherapy Acceptance: Indigenous Patient Perspectives. *Arthritis Care and Research*, **2020**, 72, 544-552	4.7	11
69	Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective Cohort. *Arthritis Care and Research*, **2020**, 72, 1104-1111	4.7	7
68	Patient Preferences for Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review. *Journal of Rheumatology*, **2020**, 47, 176-187	4.1	23
67	Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care. *BMC Health Services Research*, **2019**, 19, 572	2.9	3
66	Developing key performance indicators for prescription medication systems. *PLoS ONE*, **2019**, 14, e0210794	3.7	2
65	Position Statement: A Pragmatic Approach for Medical Cannabis and Patients with Rheumatic Diseases. *Journal of Rheumatology*, **2019**, 46, 532-538	4.1	23
64	Management of Inflammatory Arthritis in pregnancy: a National Cross-Sectional Survey of Canadian rheumatologists. *BMC Rheumatology*, **2019**, 3, 18	2.9	
63	Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. *Gastroenterology*, **2019**, 156, 1345-1353.e4	13.3	132
62	Skin cancer knowledge and photoprotective practices of organ transplant recipients. *Clinical Transplantation*, **2019**, 33, e13524	3.8	4
61	Association of Arthritis Onset with Influenza: Analysis of the Canadian Early Inflammatory Arthritis Cohort. *ACR Open Rheumatology*, **2019**, 1, 63-69	3.5	4
60	Pragmaticism of Randomized Controlled Trials of Biologic Treatment With Methotrexate in Rheumatoid Arthritis: A Systematic Review. *Arthritis Care and Research*, **2019**, 71, 620-628	4.7	8

59	Joint Estimation of Remission and Response for Methotrexate-Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis. *ACR Open Rheumatology*, **2019**, 1, 471-479	3.5	2
58	Prevalence and Characteristics of Metabolic Syndrome Differ in Men and Women with Early Rheumatoid Arthritis. *ACR Open Rheumatology*, **2019**, 1, 535-541	3.5	6
57	The RAND/PPMD Patient-Centeredness Method: a novel online approach to engaging patients and their representatives in guideline development. *European Journal for Person Centered Healthcare*, **2019**, 7, 470-475	1.3	2
56	OP0315 ACHIEVING A LOW DISEASE STATE WITHIN FIRST 3 MONTHS IN EARLY RHEUMATOID ARTHRITIS RESULTS IN LOWER FATIGUE OVER 5 YEARS **2019**,		2
55	A quarter of patients time their early rheumatoid arthritis onset differently than physicians. *RMD Open*, **2019**, 5, e000931	5.9	1
54	Palindromic Rheumatism Frequently Precedes Early Rheumatoid Arthritis: Results From an Incident Cohort. *ACR Open Rheumatology*, **2019**, 1, 614-619	3.5	3
53	Using an Online, Modified Delphi Approach to Engage Patients and Caregivers in Determining the Patient-Centeredness of Duchenne Muscular Dystrophy Care Considerations. *Medical Decision Making*, **2019**, 39, 1019-1031	2.5	14
52	GRADE guidelines: 20. Assessing the certainty of evidence in the importance of outcomes or values and preferences-inconsistency, imprecision, and other domains. *Journal of Clinical Epidemiology*, **2019**, 111, 83-93	5.7	70
51	Psoriatic arthritis screening: a systematic review and meta-analysis. *Rheumatology*, **2019**, 58, 692-707	3.9	26
50	GRADE Guidelines: 19. Assessing the certainty of evidence in the importance of outcomes or values and preferences-Risk of bias and indirectness. *Journal of Clinical Epidemiology*, **2019**, 111, 94-104	5.7	68
49	Rheum4U: Development and testing of a web-based tool for improving the quality of care for patients with rheumatoid arthritis. *Clinical and Experimental Rheumatology*, **2019**, 37, 385-392	2.2	7
48	Randomized Trials, Meta-Analyses, and Systematic Reviews: Using Examples from Rheumatology. *Rheumatic Disease Clinics of North America*, **2018**, 44, 295-305	2.4	1
47	High Adherence to System-Level Performance Measures for Rheumatoid Arthritis in a National Early Arthritis Cohort Over Eight Years. *Arthritis Care and Research*, **2018**, 70, 842-850	4.7	8
46	The Effect of Biologic and Targeted Synthetic Drugs on Work- and Productivity-related Outcomes for Patients with Psoriatic Arthritis: A Systematic Review. *Journal of Rheumatology*, **2018**, 45, 1124-1130	4.1	7
45	Measuring Patient Preferences: An Overview of Methods with a Focus on Discrete´Choice Experiments. *Rheumatic Disease Clinics of North America*, **2018**, 44, 337-347	2.4	13
44	Autoantibodies to the survival of motor neuron complex in a patient with necrotizing autoimmune myopathy. *Rheumatology*, **2018**, 57, 199-200	3.9	6
43	A Bayesian model that jointly considers comparative effectiveness research and patientsQ preferences may help inform GRADE recommendations: an application to rheumatoid arthritis treatment recommendations. *Journal of Clinical Epidemiology*, **2018**, 93, 56-65	5.7	10
42	Advances in the GRADE approach to rate the certainty in estimates from´a network meta-analysis. *Journal of Clinical Epidemiology*, **2018**, 93, 36-44	5.7	224

41	Feasibility of Measurement and Adherence to System Performance Measures for Rheumatoid Arthritis in 5 Models of Care. *Journal of Rheumatology*, **2018**, 45, 1501-1508	4.1	10
40	Practical Considerations for Using Online Methods to Engage Patients in Guideline Development. *Patient*, **2018**, 11, 155-166	3.7	12
39	Impact of Obesity on Remission and Disease Activity in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. *Arthritis Care and Research*, **2017**, 69, 157-165	4.7	88
38	The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis. *Rheumatology*, **2017**, 56, 768-776	3.9	13
37	Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis. *Inflammatory Bowel Diseases*, **2017**, 23, 461-472	4.5	33
36	Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 1291-1302	6.1	160
35	Reply. *Inflammatory Bowel Diseases*, **2017**, 23, E23-E24	4.5	
34	Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis: Republished. *Inflammatory Bowel Diseases*, **2017**, 23, E26-E37	4.5	7
33	Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 3-13	6.1	127
32	Predicting Low Disease State and Remission in Early Rheumatoid Arthritis in the First Six Months, Comparing the Simplified Disease Activity Index and European League Against Rheumatism Response Measures: Results From an Early Arthritis Cohort. *Arthritis Care and Research*, **2017**, 69, 737-741	4.7	2
31	Prevalence and risk factors for liver fibrosis detected by transient elastography or shear wave elastography in inflammatory arthritis: a systematic review. *Clinical and Experimental Rheumatology* , **2017**, 35, 1029-1036	2.2	5
30	Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. *BMJ, The*, **2016**, 353, i1777	5.9	113
29	Improving Appropriate Access to Care With Central Referral and Triage in Rheumatology. *Arthritis Care and Research*, **2016**, 68, 1547-53	4.7	23
28	The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. *Annals of the Rheumatic Diseases*, **2016**, 75, 1003-8	2.4	35
27	Association between Air Pollution and the Development of Rheumatic Disease: A Systematic Review. *International Journal of Rheumatology*, **2016**, 2016, 5356307	2	27
26	OP0179 Comparing Initial Treatment Strategies with Methotrexate on First Use of Biologic Therapy: Results from The Canadian Early Arthritis Cohort. *Annals of the Rheumatic Diseases*, **2016**, 75, 124-125	2.4	0
25	Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. *The Cochrane Library*, **2016**, CD010227	5.2	44
24	Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment. *Rheumatology*, **2016**, 55, 1959-1968	3.9	46

23	Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn disease: a network meta-analysis. *Gastroenterology*, **2015**, 148, 344-54.e5; quiz e14-5	13.3	191
22	Development of Cardiovascular Quality Indicators for Rheumatoid Arthritis: Results from an International Expert Panel Using a Novel Online Process. *Journal of Rheumatology*, **2015**, 42, 1548-55	4.1	35
21	Reply: To PMID 25448924. *Gastroenterology*, **2015**, 148, 1484	13.3	
20	Best practices for cardiovascular disease prevention in rheumatoid arthritis: a systematic review of guideline recommendations and quality indicators. *Arthritis Care and Research*, **2015**, 67, 169-79	4.7	36
19	The Rising Burden of Inflammatory Bowel Disease in North America from 2015 to 2025: A Predictive Model. *American Journal of Gastroenterology*, **2015**, 110, S829	0.7	5
18	Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH). *PLoS ONE*, **2015**, 10, e0135327	3.7	24
17	Choosing wisely: the Canadian Rheumatology Association list of 5 items physicians and patients should question. *Journal of Rheumatology*, **2015**, 42, 682-9	4.1	35
16	Non-biologic remission maintenance therapy in adult patients with ANCA-associated vasculitis: a systematic review and network meta-analysis. *Joint Bone Spine*, **2014**, 81, 337-41	2.9	20
15	Adding a "GRADE" to the quality appraisal of rheumatoid arthritis guidelines identifies limitations beyond AGREE-II. *Journal of Clinical Epidemiology*, **2014**, 67, 1274-85	5.7	12
14	Maintien de la rémission sans biothérapie chez les patients adultes atteints de vascularite «ANCA»: revue systématique de la littérature et méta-analyse en réseau. *Revue Du Rhumatisme (Edition Francaise)*, **2014**, 81, 318-323	0.1	
13	THU0255 Methotrexate Parenteral Administration versus Oral Delivery: A Comparison of Treatment Survival Using Ontario Best Practice Research Initiative (OBRI) Cohort. *Annals of the Rheumatic Diseases*, **2014**, 73, 270.3-271	2.4	
12	Prophylaxis for latent tuberculosis infection prior to anti-tumor necrosis factor therapy in low-risk elderly patients with rheumatoid arthritis: a decision analysis. *Arthritis Care and Research*, **2013**, 65, 1722-31	4.7	6
11	Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis **2013**,		2
10	Determining best practices in early rheumatoid arthritis by comparing differences in treatment at sites in the Canadian Early Arthritis Cohort. *Journal of Rheumatology*, **2013**, 40, 1823-30	4.1	24
9	Paracetamol for the management of pain in inflammatory arthritis: a systematic literature review. *Journal of rheumatology Supplement, The*, **2012**, 90, 11-6		14
8	Comparison of radiographic scoring methods in a cohort of RA patients treated with anti-TNF therapy. *Rheumatology*, **2012**, 51, 878-81	3.9	5
7	Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. *Journal of Rheumatology*, **2012**, 39, 1583-602	4.1	104
6	Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. *Journal of Rheumatology*, **2012**, 39, 1559-82	4.1	169

5	Abatacept use after failure of multiple biologic agents in patients with severe rheumatoid arthritis. *Journal of Clinical Rheumatology*, **2012**, 18, 416-8	1.1	2
4	Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. *Rheumatology*, **2012**, 51, 1416-25	3.9	43
3	Emerging issues in pharmacological management of rheumatoid arthritis: results of a national needs assessment survey identifying practice variations for the development of Canadian Rheumatology Association clinical practice recommendations. *Journal of Rheumatology*, **2012**, 39, 1555-8	4.1	8
2	Algorithm for identification of undifferentiated peripheral inflammatory arthritis: a multinational collaboration through the 3e initiative. *Journal of rheumatology Supplement, The*, **2011**, 87, 54-8		6
1	Modulation of p210(BCR-ABL) activity in transduced primary human hematopoietic cells controls lineage programming. *Blood*, **2002**, 99, 3197-204	2.2	41